熱門資訊> 正文

Larimar Therapeutics的GAAP每股收益为-0.73美元，差0.22美元

2026-03-19 19:21

Larimar Therapeutics, Inc.(LRMR) 0

Larimar Therapeutics press release (LRMR): Q4 GAAP EPS of -$0.73 misses by $0.22.
$244.5 million in pro forma cash, cash equivalents and marketable securities as of December 31, 2025, with projected cash runway into the second quarter of 2027

More on Larimar Therapeutics

Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care
Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
Larimar Therapeutics stock dips after pricing $100M share offering
Larimar Therapeutics launches proposed $75 million public offering

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。